Sebastien Hazard
Chief Tech/Sci/R&D Officer chez IMUNON, INC.
Fortune : 32 800 $ au 31/03/2024
Profil
Sebastien Hazard is currently the Chief Medical Officer & Executive Vice President at Imunon, Inc. Prior to his current position, he held the role of Senior Medical Director-Clinical Development at Tesaro, Inc. from 2016 to 2019.
From 2019 to 2021, he served as the Head-Clinical Development at GSK Plc.
Dr. Hazard then joined Bicycle Therapeutics Plc in 2021 as the Senior VP & Head-Clinical Development, a position he held until 2023.
Hazard obtained an MBA from INSEAD.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMUNON, INC.
0,21% | 07/12/2023 | 20 000 ( 0,21% ) | 32 800 $ | 31/03/2024 |
Postes actifs de Sebastien Hazard
| Sociétés | Poste | Début |
|---|---|---|
| IMUNON, INC. | Chief Tech/Sci/R&D Officer | 11/12/2023 |
Anciens postes connus de Sebastien Hazard
| Sociétés | Poste | Fin |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Corporate Officer/Principal | 01/09/2023 |
| GSK PLC | Chief Tech/Sci/R&D Officer | 01/04/2021 |
| TESARO INC | Chief Tech/Sci/R&D Officer | 01/05/2019 |
Formation de Sebastien Hazard
| INSEAD | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IMUNON, INC. | Health Technology |
| GSK PLC | Health Technology |
| BICYCLE THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
